Volunteer Spotlight: Debbie Newman

A Generational Force In 1983 when Debbie Newman and her husband Dr. Stephen Newman first received then five year old daughter Emile’s type one diabetes (T1D) diagnosis, they were frightened but also familiar with the lifestyle. “T1D care has changed dramatically since I watched my father sterilize his glass syringes by boiling them in a […]

Volunteer Spotlight: Sarah Lucas

Like many families when first faced with type 1 diabetes (T1D), Sarah Lucas and her husband Don found themselves in unfamiliar waters, anxious and overwhelmed when their daughter Mary was diagnosed in 1998. “We weren’t certain what to do, but we knew we had to do something that would help us gain a foothold, and […]

Top 10 Advances in T1D Research

JDRF-supported progress in fiscal year 2014 JDRF sets ambitious goals for progress in type 1 diabetes (T1D) research each year because our supporters inspire us to aim higher. We invite you to read about the real impact our strategic plan is making and hope you are as inspired as we are as each of these […]

Sleeping Without Fear

Study: Artificial pancreas systems with predictive low-glucose-suspend help reduce overnight hypoglycemia in individuals with type 1 diabetes Bedtime may soon be safer and a lot less anxiety filled for people with type 1 diabetes (T1D) thanks to software being developed as a next-step component for artificial pancreas systems. Called predictive low-glucose-suspend (pLGS), it interacts with […]

Merck smart insulin project advancing into clinical trials

On May 6, 2014, Merck held an investor briefing and provided updates on various strategic initiatives, including its smart insulin project acquired in 2010 when it purchased SmartCells. SmartCells — a diabetes drug-development company that received early support from JDRF — was founded in 2003 by Todd Zion, Ph.D., an MIT chemical engineer who had […]

Potential drugs for beta cell regeneration discovered

At the April 2014 JDRF-GNF (Genomics Institute of the Novartis Research Foundation) meeting, Dr. Byran Laffitte described how GNF has the potential to identify the first disease altering therapy for T1D. He presented preclinical evidence that GNF has identified the first highly effective low molecular weight regulators of beta cell proliferation. Overall, GNF has identified […]

Progress on ViaCyte’s novel encapsulated cell therapy

In February, JDRF announced it is providing additional milestone-based funding for the continued development of ViaCyte’s VC-01™ encapsulated cell therapy product candidate for the treatment of T1D. JDRF will fund up to $7 million to help ensure a rapid transition of the project into the clinical phase of development once ViaCyte’s investigational new drug application […]

Broadening T1D R&D funding sources

Last year JDRF took a number of significant actions to broaden the resources available in the T1D research and development space – three of them are highlighted here. Each of these will help speed progress towards our research goals across our portfolio of research objectives to develop and deliver novel T1D therapies to patients. In […]

Inhaled insulin shows value in artificial pancreas study

Last September, results from a JDRF-funded study were announced by Sansum Diabetes Research Institute and JDRF. This study addresses one of the key limitations of early artificial pancreas systems – the challenge of mealtime dosing of insulin. This is because insulin delivered through the skin by a pump or injections works much slower than insulin […]